A Phase 2 interventional study of Ondansetron and Placebo in CINV, sponsored by Acacia Pharma Ltd. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-25.
Sponsored by Acacia Pharma Ltd · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Comparison of efficacy of APD403 at preventing delayed sickness in patients who have received cancer chemotherapy
Acacia Pharma Ltd is the lead sponsor of 18 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adequate cardiac, hepatic and renal function
Adequate haematological function
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OND + DEX + FOS followed by oral DEX
Drug: Ondansetron · Drug: Dexamethasone · Drug: Fosaprepitant
OND + APD403 followed by oral PLACEBO
Drug: Ondansetron · Drug: Placebo · Drug: APD403 IV
OND + APD403 followed by oral APD403 low dose
Drug: Ondansetron · Drug: APD403 IV · Drug: APD403 oral
OND + APD403 followed by oral APD403 mid dose
Drug: Ondansetron · Drug: APD403 IV · Drug: APD403 oral
OND + APD403 followed by oral APD403 high dose
Drug: Ondansetron · Drug: APD403 IV · Drug: APD403 oral
5HT3-antagonist
Comparator
Corticosteroid
NK1 antagonist
Amisulpride IV 20 mg
Amisulpride oral 10, 20 or 40 mg
Number of Participants With Delayed Phase Complete Response(CR)
Delayed phase complete response (CR), defined as an absence of emetic episodes and no rescue medication use in the period from 24 to 120 hours after the initiation of chemotherapy. The primary endpoint was analysed separately in the strata of chemotherapy regimen and gender, and in the strata of country.
Time frame: 24-120 hours
Number of Participants With CR in the Overall Phase.
CR defined as no emesis and no use of rescue medication, in the overall phase (0 to 120 hours after the initiation of chemotherapy)
Time frame: 0 to 120 hours after the initiation of chemotherapy
| Milestone | Control | Placebo | APD403 10MG | APD403 20MG | ADP403 40MG |
|---|---|---|---|---|---|
| Started | 69 | 67 | 67 | 70 | 69 |
| Evaluable itt | 66 | 66 | 63 | 68 | 65 |
| Completed | 61 | 65 | 63 | 68 | 63 |
| Not completed | 8 | 2 | 4 | 2 | 6 |
Delayed phase complete response (CR), defined as an absence of emetic episodes and no rescue medication use in the period from 24 to 120 hours after the initiation of chemotherapy. The primary endpoint was analysed separately in the strata of chemotherapy regimen and gender, and in the strata of country.
| Participants | Control | PLACEBO | APD403 10MG | ADP421 20MG | APD421 40MG |
|---|---|---|---|---|---|
| Number of Participants With Delayed Phase Complete Response(CR) | 37 | 13 | 27 | 21 | 20 |
CR defined as no emesis and no use of rescue medication, in the overall phase (0 to 120 hours after the initiation of chemotherapy)
| Participants | Control | Placebo | APD403 10MG | APD403 20MG | ADP403 40MG |
|---|---|---|---|---|---|
| Number of Participants With CR in the Overall Phase. | 33 | 11 | 21 | 17 | 17 |
Collected over 7 Days. Non-serious events are listed at a 5.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Control | 2/66 (3%) | 8/66 (12.1%) | 36/66 (54.5%) |
| Placebo | 0/66 (0%) | 12/66 (18.2%) | 47/66 (71.2%) |
| APD403 10MG | 0/63 (0%) | 2/63 (3.2%) | 34/63 (54%) |
| APD403 20MG | 0/68 (0%) | 3/68 (4.4%) | 21/68 (30.9%) |
| ADP403 40MG | 0/65 (0%) | 4/65 (6.2%) | 28/65 (43.1%) |
| Event | Control | Placebo | APD403 10MG | APD403 20MG | ADP403 40MG |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 1/66 | 4/66 | 1/63 | 1/68 | 0/65 |
| Neutropenic sepsisInfections and infestations | 1/66 | 0/66 | 0/63 | 0/68 | 2/65 |
| PyrexiaGeneral disorders | 0/66 | 2/66 | 0/63 | 0/68 | 0/65 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 2/66 | 0/66 | 0/63 | 0/68 | 0/65 |
| Renal FailureRenal and urinary disorders | 0/66 | 1/66 | 1/63 | 0/68 | 0/65 |
| Chest PainGeneral disorders | 0/66 | 1/66 | 0/63 | 0/68 | 1/65 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/66 | 0/66 | 0/63 | 0/68 | 1/65 |
| VomitingGastrointestinal disorders | 1/66 | 1/66 | 0/63 | 1/68 | 0/65 |
| DizzinessNervous system disorders | 0/66 | 1/66 | 0/63 | 0/68 | 0/65 |
| NervousnessPsychiatric disorders | 0/66 | 1/66 | 0/63 | 0/68 | 0/65 |
| Event | Control | Placebo | APD403 10MG | APD403 20MG | ADP403 40MG |
|---|---|---|---|---|---|
| FatigueGeneral disorders | 13/66 | 13/66 | 13/63 | 5/68 | 11/65 |
| HeadacheNervous system disorders | 4/66 | 9/66 | 7/63 | 3/68 | 8/65 |
| ConstipationGastrointestinal disorders | 4/66 | 5/66 | 7/63 | 2/68 | 2/65 |
| DiarrhoeaGastrointestinal disorders | 4/66 | 6/66 | 3/63 | 2/68 | 2/65 |
| Mucosal DrynessGeneral disorders | 1/66 | 1/66 | 1/63 | 3/68 | 4/65 |
| PyrexiaGeneral disorders | 2/66 | 4/66 | 0/63 | 1/68 | 0/65 |
| NauseaGastrointestinal disorders | 2/66 | 4/66 | 1/63 | 1/68 | 0/65 |
| DyspepsiaGastrointestinal disorders | 2/66 | 4/66 | 0/63 | 0/68 | 1/65 |
| Decreased AppetiteMetabolism and nutrition disorders | 4/66 | 2/66 | 2/63 | 4/68 | 0/65 |
| Age, Continuous(Years) | Control ( Dexamethazon) | Placebo | APD403 10MG | APD403 20MG | ADP403 40MG | Total |
|---|---|---|---|---|---|---|
| Mean | 58.1 ± 10.38 | 57.3 ± 11.01 | 56.9 ± 11.24 | 56.6 ± 10.53 | 56.5 ± 10.59 | 57.1 ± 10.70 |
| Sex: Female, Male(Participants) | Control ( Dexamethazon) | Placebo | APD403 10MG | APD403 20MG | ADP403 40MG | Total |
|---|---|---|---|---|---|---|
| Female | 51 | 51 | 52 | 52 | 51 | 257 |
| Male | 15 | 15 | 11 | 16 | 14 | 71 |
| Race (NIH/OMB)(Participants) | Control ( Dexamethazon) | Placebo | APD403 10MG | APD403 20MG | ADP403 40MG | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 65 | 64 | 62 | 68 | 64 | 323 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 2 | 1 | 0 | 1 | 5 |
| Region of Enrollment(Participants) | Control ( Dexamethazon) | Placebo | APD403 10MG | APD403 20MG | ADP403 40MG | Total |
|---|---|---|---|---|---|---|
| Denmark | 16 | 12 | 13 | 17 | 15 | 73 |
| Germany | 23 | 23 | 19 | 21 | 22 | 108 |
| United Kingdom | 27 | 31 | 31 | 30 | 28 | 147 |
The record gives a start of Oct 2013, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2019, 4 years 1 month after primary completion. A results delay was requested in Jul 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Acacia Pharma Ltd